✉news BusinessStartups first seen 13 h ago, last 12 h ago, peak #16
Immunotherapy startup Adecto shuts down, blaming funding climate
Original: Immunotherapy startup Adecto blames ‘risk-averse funding environment’ for closing down
Adecto, an immunotherapy startup, has closed down and is attributing its collapse to what it calls a risk-averse funding environment. The company's closure adds to a string of biotech shutdowns as investors pull back from early-stage drug development, and it is drawing attention to how difficult conditions have become for clinical-stage startups seeking capital.
Why now: It highlights ongoing concerns that tight biotech funding is forcing early-stage companies to shut down.
Rank over time, top of the chart is #1. 3 snapshots from 13 h ago to 12 h ago.
Evidence
- Immunotherapy startup Adecto blames ‘risk-averse funding environment’ for closing down · Fierce Biotech
API: https://socialmediatrends-api.osmike.com/v1/trends/756354